NCT04233034 - Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes | Biotech Hunter

Enrollment

113

Participants

Timeline

Start Date

July 9, 2020

Primary Completion Date

September 15, 2022

Study Completion Date

September 30, 2022

Conditions

Type1 Diabetes

Interventions

DEVICE

HCL

Hybrid Closed Loop therapy

DRUG

verapamil 120mg tablet

verapamil tablet

DEVICE

non-HCL

Usual diabetes care

DRUG

placebo

placebo pill manufactured to mimic verapamil 120mg tablet

Trial Locations (6)

Indiana University, Indianapolis

University of Minnesota, Minneapolis

Children's Mercy Hospital, Kansas City

Barbara Davis Center, Aurora

Stanford University, Palo Alto

Yale University, New Haven